Lead management

Scorpion COO Raj Ramanan Named A "2022 Localogy Leaders Award" Winner

Retrieved on: 
Tuesday, April 12, 2022
Organization, Leadership, Marketing, Email marketing, Lead management, Chat, National Leadership Roundtable on Church Management, SALT, Ramanan (play in verse), SEO, Technology, Goal, Appointment scheduling software, Solution, Message, AI, Social media, Management, Scorpion, Advertising

SALT LAKE CITY, April 12, 2022 /PRNewswire/ -- Scorpion, a leading provider of technology and services helping local businesses thrive, today announced that its COO Raj Ramanan was named among the five winners of the 2022 Localogy Leaders award, recognizing Ramanan's unparalleled leadership over the last year.

Key Points: 
  • The 2022 Localogy Leadership Awards spotlights executives driving innovation in their organizations, client communities, and the marketplace at large.
  • "We are proud that Raj was honored by Localogy for driving ongoing innovations that help our clients succeed," said Rustin Kretz, Scorpion's Chief Executive Officer.
  • "I am honored to receive this recognition from the preeminent organization that understands and serves the needs of local businesses around the country," said Raj Ramanan, Chief Operating Officer, Scorpion.
  • Ramanan and Scorpion Chief Experience Officer Julia Cook are slated to speak at Localogy 2022 this Spring.

Late-breaking data at ACC.22 with over 1 million patients demonstrates a major gap in guideline adherence resulting in higher mortality for patients with infected CIEDs

Retrieved on: 
Monday, April 4, 2022
Consensus, Risk, Lead, Duke University, Veni, vidi, vici, Greenspan, Anguera, HRS, NYSE, Caregiver, Research, Duke University School of Medicine, AEX, Electrophysiology, American College, Extraction, Solution, Education, PHG, Lexicon, Diagnosis, Mortality, CMS, Infection, Centers for Medicare & Medicaid Services, Senior, Quality of life, ESCMID, ACC, Cardiac electrophysiology, Death, Lead management, Awareness, American College of Cardiology, Journal of the American College of Cardiology, Internal medicine, European Heart Rhythm Association score of atrial fibrillation, Assistant, Safety, Physician, Pharmaceutical industry, Medical device, Medicare, Medicine, Patient

This study highlights the life-threatening nature of device infections and the significant opportunities to improve care in these complex patients.

Key Points: 
  • This study highlights the life-threatening nature of device infections and the significant opportunities to improve care in these complex patients.
  • The opportunity to ensure all patients have access to guideline-recommended care is not only imperative, but life-saving for patients across the world.
  • Each year one million CIEDs are implanted worldwide [4] (which include pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization devices).
  • Low Rates Of Guideline Directed Care Associated With Higher Mortality In Patients With Infections Of Pacemakers And Implantable Cardioverter Defibrillators.

Philips adds to its cardiology suite of solutions at ACC 2022 with innovations to help improve patient outcomes, experiences, and care pathway effectiveness

Retrieved on: 
Thursday, March 31, 2022
ACC, Cardiology, Cardiovascular disease, Philips, Death, Degenerative disease, Growth, Lead management, NYSE, Mortality, American Heart Association, Duke University School of Medicine, AEX, Echocardiography, Assistant, Prevalence, Coronary artery disease, RTI International, Industry, Safety, Calendar, VPN, Arrhythmia, American College, Physician, Heart failure, Solution, Anxiety, Efficiency, PHG, Patient, Infection, Medical imaging, Pharmaceutical industry, Medicine

Philips cardiology portfolio offers solutions for coronary artery disease, structural heart disease, arrhythmia and heart failure.

Key Points: 
  • Philips cardiology portfolio offers solutions for coronary artery disease, structural heart disease, arrhythmia and heart failure.
  • It integrates diagnostic and interventional imaging, treatment devices, and cardiac patient monitoring solutions at each point in the patient journey with the aim to improve clinical outcomes, patient and staff experiences, and care pathway effectiveness.
  • Worldwide, clinicians need to balance the delivery of high-quality care for a growing volume of complex patients with constantly improving departmental efficiency.
  • Adding to the strength and depth of its cardiology portfolio, at ACC.22 Philips is launching two major innovations.

Monroe Capital Closes $457 Million Collateralized Loan Obligation Transaction

Retrieved on: 
Tuesday, March 22, 2022
Banking, Professional Services, Finance, Lead management, LTD, BB, BDC Building, Deutsche Bank, AAA, Consumer, Clos, Capital, AUM, CLO, Bookrunner, Bank, Security (finance), Financial services

Monroe Capital LLC (Monroe) today announced the closing of a $457 million term debt securitization known as Monroe Capital MML CLO XIII, LTD.

Key Points: 
  • Monroe Capital LLC (Monroe) today announced the closing of a $457 million term debt securitization known as Monroe Capital MML CLO XIII, LTD.
  • Monroe and its affiliates retained a majority of the Subordinated Notes in the transaction.
  • This transaction was structured to meet and comply with both the European risk retention guidelines as well as U.S. risk retention guidelines.
  • Monroe Capital LLC (Monroe) is a premier boutique asset management firm specializing in private credit markets across various strategies, including direct lending, asset-based lending, specialty finance, opportunistic and structured credit, and equity.

Caverion Corporation publishes the listing prospectus for its EUR 75 million bond; listing application submitted

Retrieved on: 
Friday, March 18, 2022
EET, Regulation, Financial Services and Markets Act 2000, Securities Act of 1933, Sale, Investment, United Kingdom, Finnish Financial Supervisory Authority, Compliance, Financial services, Nordea, Investor relations, Publication, Person, Prospectus, Documentation, Bond, Order, Lead management, EUR, Finance, AFRICA, Joint, Online gambling, Security (finance), Caverion, NEW ZEALAND

HELSINKI, March 18, 2022 /PRNewswire/ -- Caverion Corporation publishes the listing prospectus for its EUR 75 million bond; listing application submitted

Key Points: 
  • Caverion Corporation Stock Exchange Release 18 March 2022 at 1.00 p.m. EET
    HELSINKI, March 18, 2022 /PRNewswire/ -- Caverion Corporation publishes the listing prospectus for its EUR 75 million bond; listing application submitted
    Caverion Corporation ("Caverion") announced on 17 February 2022 its decision to issue a senior unsecured bond of EUR 75 million (the "Bond").
  • The Finnish Financial Supervisory Authority has today approved the listing prospectus of the Bond and Caverion has today submitted an application for the Bond to be admitted to trading on the official list of Nasdaq Helsinki Ltd.
  • The listing prospectus will be available at the latest 21 March 2022 in English on Caverion's website at https://www.caverion.com/investors/ publications.
  • DKCO Attorneys-at-law Ltd acts as legal advisor to Caverion and the Joint Lead Managers in the issue of the Bond.

Foureyes Receives 3rd Consecutive Top Rated DrivingSales Dealer Satisfaction Award

Retrieved on: 
Saturday, March 12, 2022
Industry, NADA, Marketing, Lead management, National Automobile Dealers Association, Sale, Calendar, CEO, Review, Financial adviser, Online shopping, Car dealership, Four eyes

PORTLAND, Ore., March 12, 2022 /PRNewswire-PRWeb/ -- Foureyes sales intelligence software has received a Top Rated Lead Management Award in the 12th annual DrivingSales Dealer Satisfaction Awards, presented at a special event in conjunction with the 2022 National Automobile Dealers Association (NADA) Convention & Expo.

Key Points: 
  • PORTLAND, Ore., March 12, 2022 /PRNewswire-PRWeb/ -- Foureyes sales intelligence software has received a Top Rated Lead Management Award in the 12th annual DrivingSales Dealer Satisfaction Awards, presented at a special event in conjunction with the 2022 National Automobile Dealers Association (NADA) Convention & Expo.
  • Foureyes received a top dealer satisfaction ranking in the Lead Management category, as determined by the thousands of auto dealers who are part of the DrivingSales.com community.
  • The DrivingSales Dealer Satisfaction Awards measure dealer satisfaction with vendor products and services and are based on cumulative ratings tallied and verified over the 2021 calendar year at https://www.drivingsales.com/vendor-ratings .
  • Businesses can learn more about Foureyes by visiting http://www.foureyes.io or by signing up for a free trial of Foureyes Prospect Engagement or Foureyes Safety Net .

Caverion Corporation issues a EUR 75 million bond

Retrieved on: 
Thursday, February 17, 2022
United Kingdom, Regulation, Documentation, Order, Nordea, Securities Act of 1933, AFRICA, EUR, Bond, Lead management, Compliance, EET, Joint, Sale, Person, Financial Services and Markets Act 2000, Finance, Investment, Financial services, Investor relations, Security (finance), Caverion, NEW ZEALAND

HELSINKI, Feb. 17, 2022 /PRNewswire/ -- Caverion Corporation ("Caverion") issues a senior unsecured bond of EUR 75 million (the "Bond"). The 5-year Bond matures on 25 February 2027 and it carries a fixed annual interest of 2.750 per cent and has an issue price of 99.425 per cent.

Key Points: 
  • Caverion Corporation Stock Exchange Release 17 February 2022 at 5.00 p.m. EET
    HELSINKI, Feb. 17, 2022 /PRNewswire/ -- Caverion Corporation ("Caverion") issues a senior unsecured bond of EUR 75 million (the "Bond").
  • Caverion will no later than 30 April 2022 submit an application for the Bond to be admitted to trading on the official list of Nasdaq Helsinki Ltd.
  • Nordea Bank Abp and Skandinaviska Enskilda Banken AB (publ) act as Joint Lead Managers for the issue of the Bond.
  • DKCO Attorneys-at-law Ltd acts as legal advisor to Caverion and the Joint Lead Managers in the issue of the Bond.

MyCase's Growth Strategy Bolstered by Adding Arman Samani as New Chief Product and Technology Officer

Retrieved on: 
Wednesday, February 16, 2022
Health information management, History, Ecosystem, Practice management software, Lead management, Technology, CEO, Germinated wheat, SAN, Chief technology officer, Apax Partners, Chapel Hill, Economics, Leadership, Moses Austin, Practice management, Case management, Kareo, University of North Carolina at Charlotte, LEX, Communication, Mailchimp, Acquisition, Lawyer, Global Payments, Software, Industry, Growth, Automation, Multimedia, University, Software as a service, Management, Saas

Samani joins MyCase as an accomplished industry leader with over two decades of experience in building and overseeing innovation at high-growth SaaS businesses.

Key Points: 
  • Samani joins MyCase as an accomplished industry leader with over two decades of experience in building and overseeing innovation at high-growth SaaS businesses.
  • He's a proven product visionary who will be a valuable asset as we execute on our ambitious technology roadmap and scale our business," said Jim McGinnis, CEO of MyCase.
  • Most recently, Samani was Chief Product and Strategy Officer at PatientPop where he oversaw the development and rapid expansion of a SaaS practice growth platform for physician's offices and the eventual merger of this company with Kareo.
  • Before that, he was the Chief Product and Technology Officer at AdvancedMD, where he helped grow the company's cloud-based electronic health records, practice management, and patient engagement platform.

Insellerate Receives Growth Investment Led by Argentum

Retrieved on: 
Thursday, February 10, 2022
Argentum, GLOBE, Industry, Growth, Lead management, Engagement, Automation, Board, CRM, Software, Marketing, Software as a service, Technology, Founder CEO, CEO, Life, SOC 2, Bank, Cryptocurrency, Silver

Insellerate is the first in any industry to deliver a complete CRM, Lead Management, and Engagement platform into a dynamic mobile application.

Key Points: 
  • Insellerate is the first in any industry to deliver a complete CRM, Lead Management, and Engagement platform into a dynamic mobile application.
  • "This investment will enhance our ability to continue offering industry-leading technology and services that meet the growing needs of our ever-expanding customer base," said Josh Friend, Founder & CEO of Insellerate.
  • Insellerate has experienced significant growth over the last two years.
  • Over its 30-year history, Argentum has invested in over 90 companies and supported more than 200 add-on acquisitions.

Lepu Biopharma Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange

Retrieved on: 
Thursday, February 10, 2022
Motherboard, DAR, IP, Awareness, Frost & Sullivan, ADC, Option, Quality control, Melanoma, China International Capital Corporation, CMC, PDX, Research, Company, PD-L1, NPC, Joint, Breast cancer, BTC, Therapy, NMPA, Drug discovery, Hong Kong Stock Exchange, Patent, Fragment crystallizable region, PD-1, Union, Technology, Intellectual property, Morgan Stanley, Founder, NMIBC, Control, Stomach, NSCLC, Antibody, NDA, HER2, Lead management, GMP, S. D. Warren Co. v. Maine Board of Environmental Protection, HK, HNSCC, Squamous cell carcinoma, Laboratory, Partnership, Stock exchange, Pharmaceutical industry, Property management, Fine chemical, Vaccine, UC, Limited

Established an integrated end-to-end platform across drug discovery, clinical development and CMC and GMP-compliant manufacturing

Key Points: 
  • Established an integrated end-to-end platform across drug discovery, clinical development and CMC and GMP-compliant manufacturing
    HONG KONG, Feb 10, 2022 - (ACN Newswire) - The biopharmaceutical company focusing on oncology therapeutics - Lepu Biopharma Co., Ltd. ("Lepu Biopharma" or the "Company", stock code: 2157), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange").
  • Lepu Biopharma will open for Hong Kong Public Offering in Hong Kong at 9 a.m., 10 February 2022 (Thursday), and close at 12:00 noon, 15 February 2022 (Tuesday).
  • Dealings in shares of Lepu Biopharma on the Main Board of the Hong Kong Stock Exchange is expected to commence on 23 February 2022 (Wednesday).
  • -- China International Capital Corporation Hong Kong Securities Limited and Morgan Stanley Asia Limited are the Joint Sponsors and Joint Global Coordinators.